Liquidity & Capital Structure: Vor Biopharma (VOR) maintains a strong current ratio (5.19) and quick ratio (4.96) as of 2024, with $60M in cash and equivalents. No long-term debt ensures immediate solvency, but the absence of revenue and persistent net losses ($116.9M in 2024) highlight operational fragility.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
View 5 tickers daily
Create and manage Watchlists
Import portfolios (no personalized insights)
Chat with the general Sagehood AI Agent
Market Radar: Preview access only
Premium Membership
Unlimited AI-generated insights across all sections
Market Overview
Market Radar (AI-driven investment opportunities)
Access to all Sagehood AI agents, including domain-specific experts
Personalized insights and actionable recommendations for smarter investing